Article info

Download PDFPDF
Original research
TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes

Authors

  • Mariona Terradas Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Pilar Mur Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Sami Belhadj Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Emma R Woodward Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UKDivision of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • George J Burghel Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UK PubMed articlesGoogle scholar articles
  • Pau M Munoz-Torres Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Isabel Quintana Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Matilde Navarro Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Joan Brunet Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, SpainCatalan Institute of Oncology, IDIBGi, Girona, Spain PubMed articlesGoogle scholar articles
  • Conxi Lazaro Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Marta Pineda Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • Victor Moreno Program in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainUnit of Biomarkers and Susceptibility, Cancer Prevention and Control Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Epidemiologia y Salud Pública (CIBERESP), Madrid, SpainDepartment of Clinical Sciences, Faculty of Medicine, University of Barcelona, Barcelona, Spain PubMed articlesGoogle scholar articles
  • Gabriel Capella Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  • D Gareth R Evans Manchester Centre for Genomic Medicine, St Mary's Hospital, Manchester University NHS Foundation Trust, Manchester, UKDivision of Evolution and Genomic Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Laura Valle Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Hospitalet de Llobregat, Barcelona, SpainProgram in Molecular Mechanisms and Experimental Therapy in Oncology (Oncobell), IDIBELL, Hospitalet de Llobregat, Barcelona, SpainCentro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Laura Valle, Hereditary Cancer Program, Catalan Institute of Oncology, IDIBELL, Av. Gran Via 199-203, 08908 Hospitalet de Llobregat, Barcelona, Spain; lvalle{at}idibell.cat
View Full Text

Citation

Terradas M, Mur P, Belhadj S, et al
TP53, a gene for colorectal cancer predisposition in the absence of Li-Fraumeni-associated phenotypes

Publication history

  • Received May 14, 2020
  • Revised August 19, 2020
  • Accepted August 23, 2020
  • First published September 30, 2020.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.